Impact of Vaccination in Acute COVID-19

The Impact of Vaccination in a Cohort of Patients Hospitalized for Acute COVID-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05198453

Enrollment

529

Registered

2022-01-20

Start date

2021-08-16

Completion date

2022-01-10

Last updated

2022-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The aim of this study was to evaluate the association between vaccination with one of the four SARS-CoV-2 vaccines authorized for use in the European Union-BNT162b2, ChAdOx-1S, mRNA-1273 or Ad.26.COV2.S-and progression to critically severe disease among adult patients with PCR-confirmed acute COVID-19.

Interventions

BIOLOGICALvaccination

patients who received COVID-19 vaccine

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age 18 yers or more * hospitalized for acute COVID-19 * PCR confirmed infection with SARS-CoV-2

Exclusion criteria

* hospitalized for other conditions

Design outcomes

Primary

Measure	Time frame
number (%) with critically severe disease	assessment performed at a minimum 30 days after admission

Countries

Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026